A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Launched by CELGENE · Apr 25, 2019
Trial Information
Current as of July 25, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called CC-99282, both on its own and combined with other medications, for people with relapsed or refractory non-Hodgkin lymphoma (NHL). This means it is looking at how safe the treatment is and if it can help patients whose lymphoma has not responded to previous therapies. The trial is currently recruiting participants who are between the ages of 65 and 74 and are in fairly good health, as indicated by their performance status.
To be eligible for the trial, participants must have a history of non-Hodgkin lymphoma that has come back after treatment or has not responded to treatment. They should not have any serious heart issues or conditions that would significantly shorten their life expectancy. Participants can expect regular check-ups and monitoring during the trial to ensure their safety and to see how well the treatment works. It’s a chance to access a new therapy that might provide benefits for their condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
- • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Exclusion Criteria:
- • Life expectancy ≤ 2 months
- • Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
- • Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)
- • Impaired cardiac function or clinically significant cardiac disease
- • Other protocol-defined inclusion/exclusion criteria apply
About Celgene
Celgene, now a part of Bristol Myers Squibb, is a global biopharmaceutical company dedicated to advancing innovative therapies for patients with cancer and other serious diseases. With a strong emphasis on research and development, Celgene focuses on discovering and delivering transformative medicines that address unmet medical needs. The company is committed to enhancing patient outcomes through rigorous clinical trials, cutting-edge science, and collaboration with healthcare professionals, ultimately striving to improve the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rouen, , France
Jacksonville, Florida, United States
Hackensack, New Jersey, United States
Malaga, , Spain
Saint Louis, Missouri, United States
Houston, Texas, United States
Paris, , France
Madrid, , Spain
Sao Paulo, Sp, Brazil
Salamanca, , Spain
Copenhagen, , Denmark
Buenos Aires, , Argentina
Jerusalem, , Israel
Leuven, , Belgium
Vienna, , Austria
Bologna, , Italy
Edegem, , Belgium
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
La Jolla, California, United States
Creteil, , France
Vejle, , Denmark
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Jerusalem, , Israel
Guangzhou, , China
Aarhus, , Denmark
Bordeaux, , France
Porto Alegre, Rio Grande Do Sul, Brazil
Toronto, Ontario, Canada
Bergamo, , Italy
Shenyang, Liaoning, China
Paris, , France
Napoli, , Italy
Montpellier Cedex 5, , France
Beijing, Beijing, China
Zhengzhou, Henan, China
Busan, , Korea, Republic Of
Tianjin, Tianjin, China
Villejuif Cedex, , France
Barcelona, , Spain
Napoli, , Italy
Shanghai, Shanghai, China
Milano, , Italy
Badalona (Barcelona), , Spain
Edinburgh Scotland, , United Kingdom
Salzburg, , Austria
Scottsdale, Arizona, United States
Tampa, Florida, United States
Whittier, California, United States
Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina
Seoul, , Korea, Republic Of
Madrid, , Spain
Pierre Benite Cedex, , France
Southhampton, , United Kingdom
Toulouse, , France
Shenyang, Liaoning, China
Rochester, Minnesota, United States
London, , United Kingdom
Shenyang, Liaoning, China
Leuven, , Belgium
Lillie Cedex, , France
Seoul, Seoul, Korea, Korea, Republic Of
Villejuif Cedex, , France
Overland Park, Kansas, United States
Tianjin, Tianjin, China
Guangzhou, Guangdong, China
Orange, California, United States
Mineola, New York, United States
Sankt Pölten, , Austria
Edmonton, Alberta, Canada
Montreal, , Canada
Aarhus C, , Denmark
Creteil, , France
Lillie Cedex, , France
Montpellier Cedex 5, , France
Bologna, , Italy
Barcelona, , Spain
Madrid, , Spain
Malaga, , Spain
Belfast Northern Ireland, , United Kingdom
Madrid, , Spain
Baltimore, Maryland, United States
Montpellier Cedex 5, , France
Santiago, , Chile
Paris, , France
Toulouse, , France
Jerusalem, , Israel
Petah Tikva, , Israel
Edinburgh Scotland, , United Kingdom
Los Angeles, California, United States
Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina
Buenos Aires, , Argentina
Cordoba, , Argentina
Santiago, Metropolitana, Chile
Santiago, Metropolitana, Chile
Las Condes, Santiago De Chile, Chile
Santiago, , Chile
Vejle, , Denmark
Bordeaux, , France
Sankt Pölten, , Austria
Vienna, , Austria
Bergamo, , Italy
Badalona (Barcelona), , Spain
Aarhus, , Denmark
Ramat Gan, , Israel
Milano, , Italy
Rozzano, , Italy
Houston, Texas, United States
Leuven, , Belgium
Porto Alegre, Rio Grande Do Sul, Brazil
Sao Paulo, Sp, Brazil
Sao Paulo, , Brazil
São Paulo, , Brazil
Toronto, Ontario, Canada
Las Condes, Arica Y Parinacota, Chile
Copenhagen, , Denmark
Pierre Benite Cedex, , France
Santiago De Chile, Metropolitana, Chile
Salzburg, , Austria
Edegem, , Belgium
Edmonton, Alberta, Canada
Rouen, , France
Napoli, , Italy
Salamanca, , Spain
Belfast Northern Ireland, , United Kingdom
Southhampton, , United Kingdom
Busan, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Pilar, Buenos Aires, Argentina
Buenos Aires, , Argentina
Pavia, , Italy
Recoleta, Metropolitana, Chile
Overland Park, Kansas, United States
Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina
Verona, , Italy
Haerbin, Heilongjiang, China
Hangzhou, Zhejiang, China
Xiamen, Fujian, China
Guangzhou, , China
Santiago, Rm, Chile
Beijing, Beijing, China
Guangzhou, Guangdong, China
Zhengzhou, Henan, China
Wuhan Shi, Hubei, China
Shenyang, Liaoning, China
Shenyang, Liaoning, China
Shanghai, Shanghai, China
Tianjin, Tianjin, China
Guangzhou, , China
São Paulo, , Brazil
Santiago, Metropolitana De Santiago, Chile
Montpellier, , France
Toulouse, , France
St. Polten, , Austria
São Paulo, , Brazil
Santiago, Metropolitana De Santiago, Chile
Santiago, Metropolitana, Chile
Santiago, Rm, Chile
Beijing, Beijing, China
Hackensack, New Jersey, United States
Recoleta, Metropolitana, Chile
Wuhan Shi, Hubei, China
Barcelona, , Spain
São Paulo, , Brazil
Ramat Gan, , Israel
Madrid, , Spain
Mineola, New York, United States
Saint Louis, Missouri, United States
Santiago, Metropolitana, Chile
Buenos Aires, , Argentina
Scottsdale, Arizona, United States
Jacksonville, Florida, United States
Tampa, Florida, United States
Overland Park, Kansas, United States
Rochester, Minnesota, United States
São Paulo, , Brazil
Lille, , France
Montpellier, , France
Paris, , France
Toulouse, , France
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials